Overall net revenue from sales in Q1 was $8.3 million, the company said. ・The company said that it now has funds to sustain itself till the second quarter of 2027. ・Total net revenue from sales of ...
The average one-year price target for Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) has been revised to $55.42 / share. This ...
Reports Phase 1 Data And Plans Phase 2 Study For Lyme Disease Prevention Candidate. Tonix Pharmaceuticals (NASDAQ: TNXP) announced the presentation of Phase 1 data and plans for an adaptive Phase 2 ...
View Tonix Pharmaceuticals Holding Corp. TNXP stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) presented positive Phase 3 RESILIENT data today, showcasing the efficacy of TONMYA (cyclobenzaprine HCl sublingual tablets) in fibromyalgia at ...
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor ...
About Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results